News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
761,531 Results
Type
Article (77583)
Company Profile (369)
Press Release (683563)
Multimedia
Podcasts (172)
Webinars (28)
Section
Business (195883)
Career Advice (3323)
Deals (36678)
Drug Delivery (152)
Drug Development (86916)
Employer Resources (189)
FDA (17222)
Job Trends (15950)
News (347094)
Policy (35476)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2997)
Academic (1)
Accelerated approval (38)
Adcomms (36)
Allergies (160)
Alliances (50092)
ALS (188)
Alzheimer's disease (1816)
Antibody-drug conjugate (ADC) (362)
Approvals (17419)
Artificial intelligence (609)
Autoimmune disease (179)
Automation (43)
Bankruptcy (356)
Best Places to Work (12189)
BIOSECURE Act (22)
Biosimilars (210)
Biotechnology (242)
Bladder cancer (168)
Brain cancer (66)
Breast cancer (683)
Cancer (5204)
Cardiovascular disease (465)
Career advice (2837)
Career pathing (42)
CAR-T (315)
CDC (64)
Celiac Disease (2)
Cell therapy (830)
Cervical cancer (39)
Clinical research (73828)
Collaboration (1896)
Company closure (4)
Compensation (1216)
Complete response letters (78)
COVID-19 (2989)
CRISPR (103)
C-suite (941)
Cystic fibrosis (151)
Data (6542)
Decentralized trials (2)
Denatured (51)
Depression (159)
Diabetes (545)
Diagnostics (7041)
Digital health (50)
Diversity (13)
Diversity, equity & inclusion (44)
Drug discovery (280)
Drug pricing (225)
Drug shortages (36)
Duchenne muscular dystrophy (253)
Earnings (78088)
Editorial (69)
Employer branding (25)
Employer resources (165)
Events (112932)
Executive appointments (1059)
FDA (20524)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (25)
Funding (1601)
Gene editing (222)
Generative AI (53)
Gene therapy (684)
GLP-1 (1148)
Government (5293)
Grass and pollen (8)
Guidances (389)
Healthcare (20432)
HIV (68)
Huntington's disease (52)
IgA nephropathy (88)
Immunology and inflammation (305)
Immuno-oncology (72)
Indications (124)
Infectious disease (3299)
Inflammatory bowel disease (216)
Inflation Reduction Act (16)
Influenza (129)
Intellectual property (265)
Interviews (630)
IPO (17230)
IRA (60)
Job creations (4109)
Job search strategy (2308)
JPM (71)
Kidney cancer (18)
Labor market (86)
Layoffs (651)
Leadership (42)
Legal (8522)
Liver cancer (99)
Longevity (18)
Lung cancer (704)
Lymphoma (393)
Machine learning (45)
Management (65)
Manufacturing (881)
MASH (180)
Medical device (14543)
Medtech (14603)
Mergers & acquisitions (20590)
Metabolic disorders (1445)
mRNA (197)
Multiple sclerosis (175)
NASH (23)
Neurodegenerative disease (370)
Neuropsychiatric disorders (107)
Neuroscience (3197)
Neurotech (1)
NextGen: Class of 2026 (7347)
Non-profit (5047)
Now hiring (66)
Obesity (705)
Opinion (344)
Ovarian cancer (172)
Pain (222)
Pancreatic cancer (246)
Parkinson's disease (311)
Partnered (38)
Patents (536)
Patient recruitment (536)
Peanut (64)
People (60270)
Pharmaceutical (77)
Pharmacy benefit managers (34)
Phase 1 (22676)
Phase 2 (32171)
Phase 3 (24349)
Pipeline (5773)
Policy (344)
Postmarket research (3217)
Preclinical (9926)
Press Release (69)
Prostate cancer (261)
Psychedelics (60)
Radiopharmaceuticals (307)
Rare diseases (974)
Real estate (6364)
Recruiting (79)
Regulatory (26561)
Reports (52)
Research institute (2692)
Resumes & cover letters (527)
Rett syndrome (28)
RNA editing (19)
RSV (90)
Schizophrenia (165)
Series A (272)
Series B (205)
Service/supplier (16)
Sickle cell disease (108)
Special edition (28)
Spinal muscular atrophy (175)
Sponsored (48)
Startups (3976)
State (2)
Stomach cancer (21)
Supply chain (113)
Tariffs (96)
The Weekly (119)
Vaccines (1172)
Venture capital (98)
Weight loss (482)
Women's health (100)
Worklife (22)
Date
Today (242)
Last 7 days (812)
Last 30 days (2731)
Last 365 days (31408)
2026 (4662)
2025 (31586)
2024 (36584)
2023 (41495)
2022 (52731)
2021 (57400)
2020 (56252)
2019 (50050)
2018 (38090)
2017 (35169)
2016 (34671)
2015 (39873)
2014 (32205)
2013 (30901)
2012 (30114)
2011 (30445)
2010 (29076)
Location
Africa (1072)
Alabama (89)
Alaska (7)
Arizona (270)
Arkansas (14)
Asia (45918)
Australia (8093)
California (11600)
Canada (3354)
China (1208)
Colorado (489)
Connecticut (497)
Delaware (349)
Europe (107511)
Florida (1749)
Georgia (377)
Hawaii (4)
Idaho (67)
Illinois (933)
India (75)
Indiana (542)
Iowa (22)
Japan (454)
Kansas (133)
Kentucky (43)
Louisiana (30)
Maine (72)
Maryland (1438)
Massachusetts (8408)
Michigan (341)
Minnesota (647)
Mississippi (6)
Missouri (144)
Montana (36)
Nebraska (27)
Nevada (130)
New Hampshire (87)
New Jersey (3101)
New Mexico (32)
New York (3080)
North Carolina (1605)
North Dakota (10)
Northern California (5667)
Ohio (363)
Oklahoma (23)
Oregon (44)
Pennsylvania (2360)
Puerto Rico (24)
Rhode Island (52)
South America (1419)
South Carolina (69)
South Dakota (1)
Southern California (4517)
Tennessee (178)
Texas (1835)
United States (41587)
Utah (348)
Vermont (1)
Virginia (289)
Washington D.C. (87)
Washington State (967)
West Virginia (4)
Wisconsin (120)
Wyoming (2)
761,531 Results for "emd group emd millipore st charles missouri".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug pricing
In Affordability Push, EMD Serono Joins TrumpRx While Roche Launches DTC Program
EMD Serono will offer its fertility treatments on TrumpRx at a steep discount, and Roche’s direct-to-consumer offering will cover its flu pill Xofluza.
October 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
EMD Serono Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
November 24, 2025
·
6 min read
Press Releases
EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies
October 17, 2025
·
6 min read
Press Releases
EMD Serono to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
September 18, 2025
·
19 min read
Press Releases
EMD Serono Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
June 13, 2025
·
8 min read
Press Releases
EMD Serono Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
May 23, 2025
·
19 min read
Press Releases
MilliporeSigma and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration
July 25, 2025
·
4 min read
Press Releases
EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash
May 21, 2025
·
7 min read
Genetown
EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced new research from the company’s diverse oncology portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4, Chicago.
May 23, 2024
·
32 min read
Genetown
EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of two new post-hoc analyses of tertiary endpoints from the MAGNIFY-MS study, a Phase IV, prospective, open-label study evaluating the efficacy and safety of MAVENCLAD® tablets in highly active relapsing multiple sclerosis.
February 29, 2024
·
13 min read
1 of 76,154
Next
